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Abstract
Any disruption in the intracellular functions ranging from DNA transcription to protein 
ligand binding as well as intercellular communication may cause cellular transformation 
to malignant cell in the proper microenvironment when it could escape from the immune 
system. In this chapter, specifically, genetic alterations playing role in the prostate cancer 
are intended to be reviewed briefly under the subheadings of genomic instability and the 
hallmarks of cancer which are sustaining proliferative signaling, evading growth sup-
pressors, resisting cell death, enabling the replicative immortality, inducing angiogen-
esis, activating invasion and progression to metastatic disease, reprogramming of the 
energy metabolism and evading immune destruction.
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1. Introduction
The basic molecular pathways and genetic alterations related to the cancer formation from 
normal cells irrespective of origin of tissue, are explained elsewhere in detail in many relevant 
textbooks. In this chapter, specifically, genetic alterations playing role in the prostate cancer 
are intended to be reviewed briefly under the subheadings of the hallmarks of cancer pro-
posed by Hanahan and Weinberg, in the light of up to date studies [1, 2].
The proposed hallmarks of cancer are consisted of sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing angio-
genesis, activating invasion and metastasis, reprogramming of energy metabolism and evad-
ing immune destruction [1, 2]. Underlying these hallmarks is the genome instability, which 
generates the genetic diversity promoting their acquisition [1, 2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The Cancer Genome Atlas (TCGA) research on prostate cancer figured out seven genetic sub-
types of prostate cancer [3]. Four subtypes are characterized by specific gene fusions includ-
ing whereas the rest are characterized by genetic mutations particularly in SPOP, FOXA1, and 
IDH1 genes [3]. Gene fusions mainly included ERG (46%), ETV1 (8%), ETV4 (4%), FLI1 (1%) 
and gene mutations were commonly found in SPOP (11%), FOXA1 (3%) and IDH1 (1%) [3]. 
However, still almost quarter percent are not categorized in any of them, confirming genetic 
heterogenicity of prostate cancer [3]. However, these recently suggested genetic subgroups of 
prostate cancer may fit for future clinical trials of selective medical or genetic treatments in 
relevant subgroups. Yet, it is to be noted that the presented classification does not necessarily 
mean the relevant genes either involving gene fusions or mutations are themselves cause of 
cancer formation and yet they may only represent common alterations during carcinogenesis 
driven by any other one.
In other words; any disruption in the intracellular functions ranging from DNA transcrip-
tion to protein ligand binding as well as intercellular communication may cause cellular 
transformation to malignant cell in the proper microenvironment when it could escape from 
immunity.
2. Genomic instability
Using allelotyping except the short arms of the acrocentric chromosomes, loss of heterozy-
gosity and or gene fusions were shown to be 61% in prostate cancer [4]. Common allelic 
deletions were in chromosome 16q (60%), chromosome 8p (50%), chromosome 10p (55%) and 
10q (30%). Allelic deletions of chromosomes 2, 3, 7, 12, 13, 17, 18, 22, X and Y were at lower 
frequencies, however no allelic deletions were present in any case without any of the dele-
tions in chromosomes 8, 10, or 16 [4–7]. As expected, the more chromosomal deletions were 
present, the higher histological grade was present in prostate cancer [4]. This genetic het-
erozygosity more has recently been confirmed by TCGA research as the gene fusions were 
reported in 59% of prostate cancer [3]. With more specific methods, deletion in some specific 
regions of chromosome 8p (specifically 8p11-8p21) is more common up to 50–70% in prostate 
cancer compared to others [4, 5, 8, 9]. Chromosomal region 8p11-8p21 contains over 400 genes 
(Figure 1) among which some has gained more attention in research for prostate carcinogen-
esis like NKX3.1 which is an androgen regulated prostate specific homeobox gene [10–12]. 
Conditional deletion of one or both alleles of Nkx3.1 in mice has been shown to cause pros-
tatic intraepithelial neoplasia (PIN) [13]. Even in murine epigenetic cancer models, Nkx3.1 
deficiency further increased the frequency of PIN lesions [14].
Another chromosomal alteration commonly seen, occur in chromosome 10 [4, 5, 15–19]. One 
of the common alterations (60%) is the loss of the phosphatase and tensin homolog gene 
(PTEN) on chromosome 10q23.3 which is a negative regulator of the PIK3/Akt survival path-
way [15–19]. The loss of PTEN in prostate cancer has been linked to higher Gleason grades, 
oncogenic TMPRSS2-ERG fusions, androgen-independent progression and metastasis [15–19]. 
Else, the size of PTEN deletions were classified into five distinct subtypes: (1) small interstitial 
(70 bp–789 kb); (2) large interstitial (1–7 MB); (3) large proximal (3–65 MB); (4) large  terminal 
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(8–64 MB), and (5) extensive (71–132 MB), all were flanked by low copy repetitive (LCR) 
sequences [20]. All types had some gains of 3q21.1-3q29 and deletions at 8p, RB1, TP53 and 
TMPRSS2-ERG and ones with large interstitial deletion had worse prognosis [20]. Although 
PTEN deletions seem to affect aneuploidy through PIK3/Akt pathway, some other factors act 
directly. To give a sample, NKX3.1 binds to androgen receptor at the ERG gene breakpoint 
and inhibits the recombination of TMPRSS2 and ERG gene loci. Loss of NKX3.1 favors error-
prone nonhomologous end-joining (NHEJ), further increasing TMPRSS2-ERG fusions [21]. 
Interestingly, intrinsic mechanism of the repair of DNA double-strand breaks (DSBs) driven 
by BRD4, itself may mediate the formation of oncogenic gene rearrangements by engaging 
the NHEJ pathway [22]. BRD4 belongs to the bromodomain and extra-terminal (BET) family 
of chromatin reader proteins that bind acetylated histones. These findings further outline 
importance of de novo alterations occurring synchronously are important for carcinogenesis 
together with error-prone intrinsic DNA repair mechanisms.
Again, the deletion of 16q23-q24 which is one of the most frequent genetic aberrations is 
associated with poor prognostic factors like advanced tumor stage, high Gleason grade, 
accelerated cell proliferation lymph node metastases and positive surgical margin [7, 23, 24]. 
Having ERG fusions were associated with higher incidence of 16q deletions [7, 23, 24]. Also, 
deletion of chromosome 13q occurs up to 50% of prostate cancer and its importance lies in 
the fact that this region contains RB transcriptional corepressor 1 gene which an important 
negative regulator of the cell cycle and the first tumor suppressor gene found [25, 26]. As 
well, deletion of three loci between 13q14.2 and 13q14.3 is associated with early biochemical 
relapse [27].
Figure 1. Some of the important genes located in 8p11-8p21 which are deleted up to 50–70% of prostate cancer (from 
http://www.ensembl.org).
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Other than structural chromosomal aberrations like aneuploidy, translocation, etc. epigenetics 
is another issue considered in carcinogenesis. The term “field cancerization” which had been 
suggested for head and neck cancers for the first time, refers to multifocal presence of genetic 
aberrations necessary for malignant transformation in a given tissue [28].
This term is also valid for prostate cancer, as cancerous tissues are multifocal with varying 
Gleason scores and preneoplastic tissues like high grade prostatic intraepithelial neoplasia 
(HGPIN) are detected closer to cancerous tissues [29]. This is further confirmed by methyla-
tion studies [30–35]. In a study comparing methylation status of GSTP1, MGMT, p14/ARF, 
p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2 and CRBP1 genes among prostate cancer, 
HGPIN and BPH tissues, methylation was increased significantly from BPH to HGPIN and 
to prostate cancer [30]. Quantitative methylation specific PCR study of radical prostatectomy 
specimens, methylation of some genes like APC, RARb2 and RASSF1A were continuous in 
the histopathologically normal tissue around the cancerous tissue, forming a methylation 
halo up to 3 mm [31]. Another study including microarray study of methylation of large num-
bers of genes, the length of the halo was detected to be up to 10 mm [32].
3. Microenvironment
Prostatic stromal microenvironment is important for normal organogenesis as well as sup-
porting carcinogenesis and the survival of the cancer cells [36, 37]. However, the exact path-
ways and stroma-tumoral interactions are poorly understood and still needed to be further 
clarified.
Cultured fibroblasts from regions close to prostate cancer cells were shown to induce tumor 
progression of initiated nontumorigenic epithelial cells both in an in vivo tissue recombi-
nation system and in an in vitro coculture system [38, 39]. Prostatic carcinoma-associated 
fibroblasts secrete SDF-1 which activates Akt pathway in the via the TGF-beta-regulated 
CXCR4 [40]. That is, TGF-beta promotes tumor formation although it has primarily growth-
inhibitory action [40]. Marked reactive stroma is associated with poor prognosis in clinically 
localized prostate cancer and microarray gene expression analysis detected higher expression 
of 544 genes and lower expression of 606 genes in the reactive stroma, all of which have vari-
ous functions like neurogenesis, axon genesis and DNA damage repair pathways [41]. In a 
recent study evaluating the nuclear and mitochondrial DNA integrity of prostate cancer cells, 
prostate cancer-associated stroma detected copy-neutral diploid genome with only rare and 
small somatic copy-number aberrations in contrast to several small somatic copy-number 
aberrations in prostate cancer cells [42]. This indicates, that above-mentioned gene expression 
changes in prostate cancer-adjacent stroma seem to be not related to frequent or recurrent 
genomic alterations in the tumor microenvironment [42].
Also, metabolic status of the prostatic stromal microenvironment has been suggested to influ-
ence the tumorigenic potential of the tumor epithelial compartment [43]. As well, it has been 
shown that the loss of the signaling adapter, p62, in stromal cells triggered an inflammatory 
response, activating cancer-associated fibroblasts which promotes tumor formation in vitro 
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and in vivo. Loss of p62 resulted in lower mTORC1 activity and deregulation of metabolic 
pathways related to the inflammation [44].
One interesting study, chronic bacterial inflammation with inoculated Escherichia coli bacte-
ria induced focal prostatic glandular atypia/ prostatic intraepithelial neoplasia in male C3H/
HeOuJ mice, suggesting a link between inflammation and prostatic neoplasia [45].
4. Sustaining proliferative signaling
To keep normal tissue architecture and function normal cells need to control proliferative 
signaling. However, in cancer cells, proliferative signaling is sustained to keep their growth. 
This is accomplished by either increased paracrine stimulation or excessive response to hor-
mones by altered receptor matching or deregulated pathways. Insulin has been shown to 
activate insulin activated the insulin receptor (INSR) in case of inhibition of the IGF1 recep-
tor (IGF1R) [46]. Mitochondrial redox signaling by p66Shc-ROS pathway has been shown to 
promote androgen-induced prostate cancer cell proliferation. As well, dihydrotestosterone 
was shown to increase the translocation of p66Shc into mitochondria and its interaction with 
cytochrome c [47]. The phosphatidylinositol 3′-kinase (PI3K) pathway has been suggested 
to be a dominant growth factor-activated cell survival pathway in prostate carcinoma cells. 
Apoptosis induced by PI3K inhibition has been shown to be reduced by either dihydrotestos-
terone or ErbB1 activating ligands which are epidermal growth factor, transforming growth 
factor alpha, and heparin-binding EGF-like growth factor [48]. Smad1 acts as a substrate for 
MAPKs and plays a central role in transmitting signals from the pathways of bone morphoge-
netic proteins. Deregulation of the pathways of bone morphogenetic proteins and activation 
of the ERK/MAP kinase (MAPK) pathway by growth factors was suggested to promote the 
development and progression of prostate cancer [49].
5. Evading growth suppressors and resisting cell death
In general sense, cancer cells need to gain new capabilities to suppress or bypass cell cycle check-
points that negatively regulate the cell proliferation and promote apoptosis. Chromosome 17p 
includes an important gene, TP53 which encodes a tumor suppressor protein, p53, containing 
transcriptional activation, DNA binding, and oligomerization domains and it functions in 
cellular stresses to induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in 
metabolism. Deletion of chromosome 17p occurs mainly in advanced stages of prostate cancer 
and metastatic prostate cancer rather that early invasive prostate cancer [50–52]. BCL2 gene 
located in 18q21.33, encodes an integral outer mitochondrial membrane protein which blocks 
apoptosis. Its overexpression occurs in advanced, hormone-refractory disease [53].
Functional loss of CDKN1B which maps to 12p13.1 is prevalent in prostate cancer [54]. It inhib-
its cyclin-dependent kinase (CDK), sharing similarity with another inhibitor CDKN1A/p21. 
The encoded protein prevents the activation of cyclin E-CDK2 or cyclin D-CDK4  complexes, 
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in this way it controls the cell cycle progression at G1 stage. It is degraded through CDK 
dependent phosphorylation and subsequent ubiquitination by SCF complexes, permitting 
cellular transition from quiescence to the proliferative state. Its inactivation in prostate cancer 
is done by expression loss or increased degradation by abnormal phosphorylation and ubiq-
uitinylating, rather than being mutated [55, 56].
Cyclin dependent kinase inhibitor 2A (CDKN2A) located in 9p21.3 encodes three alternatively 
spliced variants two of which encode structurally related isoforms functioning as inhibitors of 
CDK4 kinase and one variant functioning as stabilizer of the tumor suppressor protein p53. 
It is also rarely mutated in early prostate cancer, mainly mutated in advanced disease [57].
6. Enabling replicative immortality
Telomeres are located at the ends of eukaryotic linear chromosomes to protect chromosomes 
from end-to-end fusions and protect against the loss of terminal DNA during cell division [58]. 
Telomerase which is a ribonucleoprotein polymerase, maintains telomere length dur-
ing cell divisions by addition of the telomere repeat TTAGGG [59]. Therefore, telomerase 
is also important for the maintenance of chromosomal stability and cellular immortality. 
The enzyme consists of a protein component with reverse transcriptase activity, telomerase 
reverse transcriptase (TERT) for adding telomeric DNA repeats onto chromosome ends and 
an RNA component (TERC) for adding telomeric DNA repeats onto chromosome ends [60, 61] 
Telomerase activity was detected in prostate cancer and high-grade prostatic intraepithelial 
neoplasia [62, 63]. Both TERT and TERC activities are important in telomere maintenance. 
Knockdown of TERC by siRNA has been shown to reduce proliferation of prostate cancer 
cells and increased TERC expression which is regulated by MYC, was detected in prostate 
cancer [64]. In benign prostatic hyperplasia, PIN and prostate cancer, high levels of telomere 
dysfunction were detected, and it was suggested that telomere dysfunction may play a role in 
carcinogenesis through genomic instability [65].
7. Inducing angiogenesis
As in any kind of tumoral tissue, tissue needs more blood supply as it grows uncontrolled. 
Therefore, cancer cells need to regulate pathways to induce angiogenesis. In prostate can-
cer related angiogenesis, ps20 which is a TGF-beta1-induced regulator of angiogenesis, has 
been suggested to promote endothelial cell migration and/or pericyte stabilization of newly 
formed vascular structures [66]. As well, stromal expression of connective tissue growth factor 
also promotes angiogenesis and therefore prostate cancer progression. Expression of CTGF 
in tumor-reactive stroma has been shown to induce increased micro-vessel density. CTGF 
which is also a downstream mediator of TGF-beta1 seem to be another important regulator of 
angiogenesis in the tumor-reactive stromal microenvironment [67].
Prostate Cancer8
8. Activating invasion and metastasis
Epithelial cancers progress to higher pathological grades of malignancy carcinomas and 
become locally invasive and metastatic to distant locations. This is termed as epithelial to 
mesenchymal cell transition during which the, the associated cancer cells alter their shape, 
their attachment to other cells and the extracellular matrix.
Abnormal increased expression of the mitochondrial ribosomal protein S18-2 has been shown 
to induce epithelial to mesenchymal cell transition in prostate cancer through the TWIST2/
E-cadherin signaling and induce CXCR4-mediated migration of prostate cancer cells [68]. 
MiRNALet-7a has been shown to induce invasion of prostate cancer cells and induce migra-
tion by stimulating epithelial-mesenchymal transition through CCR7/MAPK pathway [69]. 
Interestingly, inactivation of the androgen receptor resulted in lower expression of a tran-
scriptional repressor (SAM pointed domain-containing ETS transcription factor, SPDEF) of 
CCL2, which mediates epithelial to mesenchymal cell transition of the prostate cancer cells. 
That may explain progression to metastatic stage in a subset of castration resistant prostate 
cancer [70].
9. Reprogramming of energy metabolism
It has been shown that energy metabolism of early prostate cancers mainly depends on lipids 
and other energetic molecules for energy production and not on aerobic respiration or aerobic 
glycolysis (Warburg effect) [71]. Initially defined by Otto Warburg, the Warburg effect defines 
increased rate of glucose uptake, lactate production in proliferating cells in the presence of 
oxygen and fully functioning mitochondria [72]. The Warburg effect is the first defined energy 
metabolism of cancer cells energy [72]. However, in prostate cancer that is not the matter, as 
prostate cancer cells do not have increased glucose uptake except advanced stage disease [73].
In the advanced stages, reduced mtDNA content is a critical step in the metabolism restruc-
turing for cancer cell progression. As, MtDNA depleted prostate cancer cells exhibit Warburg 
effect [74]. Reduced microRNA-132 (miR-132) expression was suggested to cause metabolic 
switch in prostate cancer cells by inhibiting Glut1 expression which results increased rate of 
lactate formation, cellular glucose uptake and the rapid growth of the cancer cells [75].
10. Evading immune destruction
The immune system acts a barrier to tumor formation and progression. The role of immune 
system is clear when increased malignancies in transplant patients is considered. In patients 
with renal transplants, genitourinary malignancies are the third most common malignancy 
after skin malignancies and lymphoproliferative disorders [76–78].
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Cancer cell transfer extracellular vesicle-mediated estrogen receptor-binding fragment-
associated antigen 9 (EBAG9) to their microenvironment promoting self-immune escape 
and further progression. EBAG9 suppresses T-cell infiltration into tumor in vivo and limits 
T-cell cytotoxicity [79]. Interestingly, the adaptive immune system was suggested to promote 
de novo prostate carcinogenesis in a human c-Myc transgenic mouse model [80]. Recently, 
tumoral exosome-immune cell cross-talk has been suggested [81]. Prostate-cancer-derived 
exosomal prostaglandin E2 (PGE2) was suggested to result impaired CD8+ T cell response 
immunosuppression via exosomal regulation of dendritic cell function [81]. Exosomal PGE2 
triggered potently the expression of CD73, an ecto-5-nucleotidase responsible for AMP to 
adenosine hydrolysis, on dendritic cells. CD73 induction of dendritic cell resulted in an ATP-
dependent inhibition of TNFα- and IL-12-production [81].
11. Conclusions
Above briefly mentioned properties of prostate cancer cells and related genes, genetic path-
ways and their interactions have still no specific clinical use in prostate cancer management.
Yet, we are too far to understand the exact genetic mechanisms underlying prostate carcino-
genesis. But, it is sure that as we progress in further researches we will be more surprised to 
find out unknown interactions of supposed to be well known genetic mechanism.
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